OBJECTIVE: Chemotherapy-induced alopecia, a common and distressing side effect of chemotherapy, may be prevented by scalp cooling, which reduces toxicity of cytostatics in hair root cells. This is the first study designed to assess the effect of scalp cooling on well-being. METHODS: A prospective multi-centre study was performed in 13 hospitals. Breast cancer patients treated with (N=98) and without (N=168) scalp cooling completed questionnaires (EORTC QLQ-C30 and EORTC-QLQ-BR23, BIS, MBA, HADS) before chemotherapy, and three weeks and six months after the last chemotherapy cycle. RESULTS: Scalp cooling was effective in 52% of the cases. Alopecia was considered among the most distressing problems at all three moments of measurement. A trend towards higher well-being was found in successfully scalp-cooled patients, as indicated by a general better health-related quality of life and better body image, whereas unsuccessfully scalp-cooled patients reported lowest well-being. CONCLUSIONS: Scalp cooling contributes not only to the well-being of successfully scalp-cooled patients but also seems to cause additional distress when patients lose their hair despite scalp cooling. This might be related to disappointment due to alopecia despite scalp cooling or possibly to a general higher biological availability of cytostatics. We recommend additional support for patients when scalp cooling is not successful and to spend more effort to maximise the effectiveness of scalp cooling. Copyright (c) 2009 John Wiley & Sons, Ltd.
OBJECTIVE: Chemotherapy-induced alopecia, a common and distressing side effect of chemotherapy, may be prevented by scalp cooling, which reduces toxicity of cytostatics in hair root cells. This is the first study designed to assess the effect of scalp cooling on well-being. METHODS: A prospective multi-centre study was performed in 13 hospitals. Breast cancerpatients treated with (N=98) and without (N=168) scalp cooling completed questionnaires (EORTC QLQ-C30 and EORTC-QLQ-BR23, BIS, MBA, HADS) before chemotherapy, and three weeks and six months after the last chemotherapy cycle. RESULTS: Scalp cooling was effective in 52% of the cases. Alopecia was considered among the most distressing problems at all three moments of measurement. A trend towards higher well-being was found in successfully scalp-cooled patients, as indicated by a general better health-related quality of life and better body image, whereas unsuccessfully scalp-cooled patients reported lowest well-being. CONCLUSIONS: Scalp cooling contributes not only to the well-being of successfully scalp-cooled patients but also seems to cause additional distress when patients lose their hair despite scalp cooling. This might be related to disappointment due to alopecia despite scalp cooling or possibly to a general higher biological availability of cytostatics. We recommend additional support for patients when scalp cooling is not successful and to spend more effort to maximise the effectiveness of scalp cooling. Copyright (c) 2009 John Wiley & Sons, Ltd.
Authors: Hope S Rugo; Paula Klein; Susan Anitra Melin; Sara A Hurvitz; Michelle E Melisko; Anne Moore; Glen Park; Jules Mitchel; Erika Bågeman; Ralph B D'Agostino; Elizabeth S Ver Hoeve; Laura Esserman; Tessa Cigler Journal: JAMA Date: 2017-02-14 Impact factor: 56.272
Authors: Manon M C Komen; Corina J G van den Hurk; Johan W R Nortier; Tjeerd van der Ploeg; P Nieboer; Jacobus J M van der Hoeven; Carolien H Smorenburg Journal: Support Care Cancer Date: 2018-09-11 Impact factor: 3.603
Authors: C Paterson; M Kozlovskaia; M Turner; K Strickland; C Roberts; R Ogilvie; G Pranavan; P Craft Journal: J Cancer Surviv Date: 2020-07-18 Impact factor: 4.442
Authors: Rowena E Vleut; Joyce E A M van Poppel; Marcus W Dercksen; Mijke Peerbooms; Saskia Houterman; Wim P M Breed Journal: Support Care Cancer Date: 2013-01-22 Impact factor: 3.603
Authors: Manon M C Komen; Wim P M Breed; Carolien H Smorenburg; Tjeerd van der Ploeg; S H Goey; Jacobus J M van der Hoeven; Johan W R Nortier; Corina J G van den Hurk Journal: Support Care Cancer Date: 2016-01-25 Impact factor: 3.603